Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2019

View Archived Issues

Same compound inhibits wild-type, activates mutant MALT1

Membrane rips kill axons in MS

Transcriptional CDK inhibitors downregulate brachyury in chordoma

PVRIG and TIGIT regulate CD8+ T cells/tumor cells interaction and can be a target for immunotherapy

REST-regulated gene secretagogin as a novel prognostic biomarker in prostate cancer

New cyclopeptides containing N-methyl amino acids with activity against several P. falciparum stages

Denali enzyme therapy for MPS II crosses the blood-brain barrier

University of Texas System divulges ATR kinase inhibitors

MEK/ERK2 pathway regulates Shank3 stability: a novel target for SHANK3-related disorders

ArmaGen arylsulfatase A fusion protein shows promise for metachromatic leukodystrophy

Misplaced energy turns T cells proinflammatory

Positive results announced from phase I study of LY-3056480 in sensorineural hearing loss

Updated clinical data presented from ongoing studies of AVR-RD-01 gene therapy for Fabry disease

Early cardiac hypertrophy seen in murine model of Pompe disease

FDA approves Cablivi for treatment of aTTP

Inhibrx begins first-in-human study of INBRX-105 bispecific antibody for cancer

U.S. researchers present new compounds for tuberculosis

ProtNeteomix identifies new EGFR degradation inducers

Evotec and Galapagos collaborate on small-molecule fibrotic disease program

Sichuan Haisco Pharmaceutical describes kappa-opioid receptor agonists

ReViral presents RSV fusion inhibitors as new antivirals

Axsome reaches SPA agreement with FDA on phase III trial for AXS-07 for acute migraine

Arch Oncology initiates phase I trial of AO-176 in select solid tumors

Roche conducts phase I trial of RO-7239958 for chronic HBV infection

Solid seeks to escalate dose in IGNITE DMD trial of SGT-001 following preliminary findings

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...